Detalles de la búsqueda
1.
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med
; 387(8): 715-726, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36001712
2.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Ann Rheum Dis
; 82(12): 1516-1526, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699654
3.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Ann Rheum Dis
; 82(12): 1527-1537, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696589
4.
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Ann Rheum Dis
; 82(6): 773-787, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35953263
5.
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Ann Rheum Dis
; 81(12): 1661-1668, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36109142
6.
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Ann Rheum Dis
; 80(4): 432-439, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33148701
7.
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Ann Rheum Dis
; 80(1): 71-87, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33158881
8.
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Rheumatology (Oxford)
; 59(10): 2774-2784, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32031665
9.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Ann Rheum Dis
; 78(11): 1454-1462, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31362993
10.
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1ß dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.
Ann Rheum Dis
; 78(3): 413-420, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30552176
11.
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.
J Immunol
; 198(10): 3809-3814, 2017 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28389592
12.
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
Ann Rheum Dis
; 82(2): 161-163, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36609341
13.
Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus.
J Immunol
; 197(7): 2854-63, 2016 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27534558
14.
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Clin Exp Rheumatol
; 34(1): 32-6, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26575982
15.
Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
Clin Exp Rheumatol
; 34(4): 625-33, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27087059
16.
EULAR PsA management recommendations 2019: can the recommendations be improved?
Ann Rheum Dis
; 79(6): 680-682, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32434811
17.
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.
Ann Rheum Dis
; 74(6): 1037-44, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24550168
18.
Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.
Ann Rheum Dis
; 73(1): 161-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23300117
19.
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Ann Rheum Dis
; 73(9): 1626-34, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24297381
20.
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Ann Rheum Dis
; 72(9): 1461-8, 2013 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23268367